Recent investigations have converged on the intersection of GLP-1|GIP|glucagon receptor agonist therapies and dopaminergic communication. While GLP stimulators are commonly employed for managing type 2 diabetes mellitus, their potential consequences on motivation circuits, specifically governed by dopaminergic systems, are receiving significant int